EVENITY

PeakmAb

romosozumab-aqqg

BLAINJECTIONINJECTABLE
Approved
Apr 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5

Mechanism of Action

sclerostin, a regulatory factor in bone metabolism. EVENITY increases bone formation and, to a lesser extent, decreases bone resorption. Animal studies showed that romosozumab-aqqg stimulates new bone formation on trabecular and cortical bone surfaces by stimulating osteoblastic activity resulting…

Clinical Trials (5)

NCT05972551Phase 3Recruiting

Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta

Started Apr 2024
106 enrolled
Osteogenesis Imperfecta
NCT06079476Phase 4Completed

A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.

Started Oct 2023
100 enrolled
Postmenopausal Osteoporosis
NCT04545554Phase 1Completed

Study to Evaluate Romosozumab in Children and Adolescents With Osteogenesis Imperfecta

Started Jan 2021
25 enrolled
Osteogenesis Imperfecta
NCT01588509Phase 1Completed

Transition From Alendronate to Romosozumab (AMG 785)

Started Mar 2012
60 enrolled
Osteoporosis
NCT00907296Phase 2Completed

Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing

Started Sep 2009
402 enrolled
Fracture Healing